Mindray Medical Misses on Q1 Earnings - Analyst Blog

By Zacks Equity Research,

Shutterstock photo

Chinese medical devices maker, Mindray Medical International Ltd. ( MR ) posted a disappointing 34.0% fall in adjusted earnings per share to 33 cents for the 2014-first quarter from 50 cents a year ago and missed the Zacks Consensus Estimate by 3 cents per share.

Adjusted net earnings dipped 35.7% year-over-year to $38.5 million from $59.8 million in the first quarter of 2013. Reported earnings decreased 37.5% to 30 cents per share from 48 cents per share in the 2013-quarter or 37.9% to $35.6 million from $57.4 million in the year-ago quarter.

Net revenues grew 9.4% to $264.8 million, lying below the Zacks Consensus Estimate of $291 million. International sales continued to be stronger than the domestic market sales.  

International revenues upped 13.9% to $148.9 million while revenues from China grew at a slower pace of 4.0% to $115.8 million due to sluggish purchasing and marketing activities in the healthcare sector.

Segment Revenues

Revenues from Patient Monitoring & Life Support Products fell 1.4% to $98.0 million, contributing 37.0% to overall net revenues. Revenues from In-Vitro Diagnostic Products went up 6.8% to $73.0 million, contributing 27.6% to net revenues. Reagents sales accounted for 38.1% of segment revenues.

Revenues from Medical Imaging Systems escalated 27.1% to $67.6 million, contributing 25.5% to net revenues. Revenues from Others (including sales from the orthopedics business, service revenues from extended warranties, sales of accessories and repair service revenues for post-warranty period) zoomed 23.6% to $26.2 million, contributing 9.9% to overall net revenues.


Adjusted gross profit rose 5.3% to $148.0 million but adjusted gross margin declined 210 basis points (bps) to 55.9% in the quarter. Adjusted operating profit went down 16.5% to $34.7 million, while operating margin dipped 410 bps to 13.1% from 17.2% in the 2013 first quarter.

Financial Position

MR had $419.8 million in cash and cash equivalents as of Mar 31, 2014, up 9.0% from $385.2 million as of Dec 31, 2013. Total bank loans fell 10.6% to $425.2 million from $475.7 million as of Dec 31, 2013.

In the quarter, cash flow from operating activities plunged 53.6% to $19.7 million from $42.4 million in the 2013-quarter. Capital expenditure rose 39.1% to $27.9 million compared with $20.0 million a year ago.

2014 Guidance

MR continues to expect 2014 net revenues to grow at least 15% over 2013 based on strengths in Western Europe and some emerging markets as well as gradual improvement in China. The company also reiterated its capital expenditures guidance of $160 million for the year.

Our Take

MR is a bellwether in the Chinese MedTech industry with a solid international presence. A key distinction with domestic competitors is that the majority of its products have CE Mark and/or Food and Drug Administration (FDA) clearance.

However, falling earnings disappointed investors and the company's results fell short of both the earnings and revenues estimates. Currently, MR carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Accuray Inc. ( ARAY ) and Edwards Lifesciences Corp. ( EW ). While Delcath Systems sports a Zacks Rank #1 (Strong Buy), both Accuray and Edwards Lifesciences retain Zacks Rank #2 (Buy).

ACCURAY INC (ARAY): Free Stock Analysis Report

DELCATH SYS INC (DCTH): Free Stock Analysis Report

EDWARDS LIFESCI (EW): Free Stock Analysis Report

MINDRAY MEDICAL (MR): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Earnings , Stocks
Referenced Stocks: ARAY , DCTH , EW , MR

More from Zacks.com




Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com